Karn Wijarnpreecha1, Charat Thongprayoon2, Supavit Chesdachai3, Panadeekarn Panjawatanana4, Patompong Ungprasert5, Wisit Cheungpasitporn6. 1. Department of Internal Medicine, Bassett Medical Center, One Atwell Road, Cooperstown, NY, 13326, USA. 2. Department of Internal Medicine, Bassett Medical Center, One Atwell Road, Cooperstown, NY, 13326, USA. charat.thongprayoon@gmail.com. 3. Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 4. Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. 5. Division of Rheumatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 6. Division of Nephrology, University of Mississippi Medical Center, Jackson, MS, USA.
Abstract
BACKGROUND/AIMS: The aim of this meta-analysis was to assess the risks of chronic kidney disease (CKD) and/or end-stage kidney disease (ESRD) in patients who are taking proton-pump inhibitors (PPIs) and/or H2 receptor antagonists (H2RAs). METHODS: Comprehensive literature review was conducted utilizing MEDLINE and EMBASE databases through April 2017 to identify all studies that investigated the risks of CKD or ESRD in patients taking PPIs/H2RAs versus those without PPIs/H2RAs. Pooled risk ratios (RR) and 95% confidence interval (CI) were calculated using a random-effect, generic inverse variance method of DerSimonian and Laird. The protocol for this study is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42017067252). RESULTS: Five studies with 536,902 participants were patients were identified and included in the data analysis. When compared with non-PPIs users, the pooled risk ratio (RR) of CKD or ESRD in patients with PPI use was 1.33 (95% CI 1.18-1.51). Pre-specified subgroup analysis (stratified by CKD or ESRD status) demonstrated pooled RRs of 1.22 (95% CI 1.14-1.30) for association between PPI use and CKD and 1.88 (95% CI 1.71-2.06) for association between PPI use and ESRD, respectively. However, there was no association between the use of H2RAs and CKD with a pooled RR of 1.02 (95% CI 0.83-1.25). When compared with the use of H2RAs, the pooled RR of CKD in patients with PPI use was 1.29 (95% CI 1.22-1.36). CONCLUSIONS: Our study demonstrates statistically significant 1.3-fold increased risks of CKD and ESRD in patients using PPIs, but not in patients using H2RAs.
BACKGROUND/AIMS: The aim of this meta-analysis was to assess the risks of chronic kidney disease (CKD) and/or end-stage kidney disease (ESRD) in patients who are taking proton-pump inhibitors (PPIs) and/or H2 receptor antagonists (H2RAs). METHODS: Comprehensive literature review was conducted utilizing MEDLINE and EMBASE databases through April 2017 to identify all studies that investigated the risks of CKD or ESRD in patients taking PPIs/H2RAs versus those without PPIs/H2RAs. Pooled risk ratios (RR) and 95% confidence interval (CI) were calculated using a random-effect, generic inverse variance method of DerSimonian and Laird. The protocol for this study is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42017067252). RESULTS: Five studies with 536,902 participants were patients were identified and included in the data analysis. When compared with non-PPIs users, the pooled risk ratio (RR) of CKD or ESRD in patients with PPI use was 1.33 (95% CI 1.18-1.51). Pre-specified subgroup analysis (stratified by CKD or ESRD status) demonstrated pooled RRs of 1.22 (95% CI 1.14-1.30) for association between PPI use and CKD and 1.88 (95% CI 1.71-2.06) for association between PPI use and ESRD, respectively. However, there was no association between the use of H2RAs and CKD with a pooled RR of 1.02 (95% CI 0.83-1.25). When compared with the use of H2RAs, the pooled RR of CKD in patients with PPI use was 1.29 (95% CI 1.22-1.36). CONCLUSIONS: Our study demonstrates statistically significant 1.3-fold increased risks of CKD and ESRD in patients using PPIs, but not in patients using H2RAs.
Authors: Michael D Howell; Victor Novack; Philip Grgurich; Diane Soulliard; Lena Novack; Michael Pencina; Daniel Talmor Journal: Arch Intern Med Date: 2010-05-10
Authors: Philip O Katz; Kerry B Dunbar; Felice H Schnoll-Sussman; Katarina B Greer; Rena Yadlapati; Stuart Jon Spechler Journal: Am J Gastroenterol Date: 2022-01-01 Impact factor: 10.864
Authors: João Victor Marques Guedes; Jéssica Azevedo Aquino; Tássia Lima Bernardino Castro; Flávio Augusto de Morais; André Oliveira Baldoni; Vinícius Silva Belo; Alba Otoni Journal: PLoS One Date: 2020-03-04 Impact factor: 3.240
Authors: Dennis G Moledina; F Perry Wilson; Lidiya Kukova; Wassim Obeid; Randy Luciano; Michael Kuperman; Gilbert W Moeckel; Michael Kashgarian; Mark A Perazella; Lloyd G Cantley; Chirag R Parikh Journal: Nephrol Dial Transplant Date: 2021-09-27 Impact factor: 5.992
Authors: Benjamin Scally; Jonathan R Emberson; Enti Spata; Christina Reith; Kelly Davies; Heather Halls; Lisa Holland; Kate Wilson; Neeraj Bhala; Christopher Hawkey; Marc Hochberg; Richard Hunt; Loren Laine; Angel Lanas; Carlo Patrono; Colin Baigent Journal: Lancet Gastroenterol Hepatol Date: 2018-02-21